Clinical control study of Escitalopram Oxalate and Sertraline combined with cognitive behavior in the treatment of adolescent depression
ZOU Liang1 ZHANG Xingong2 SUN Lili3 ZHANG Lingling4▲ WANG Hanyu2
1.Department of Pharmacy, the Third People’s Hospital of Fuyang, Anhui Province, Fuyang 236000, China;
2.Department of Anxiety Disorders, the Third People’s Hospital of Fuyang, Anhui Province, Fuyang 236000, China;
3.Department of Sleep Medicine, the Third People’s Hospital of Fuyang, Anhui Province, Fuyang 236000, China;
4.Department of Pharmacy, the Second People’s Hospital of Fuyang, Anhui Province, Fuyang 236000, China
Abstract:Objective To investigate the clinical efficacy of Escitalopram Oxalate and Sertraline combined with cognitive behavior in the treatment of adolescent depression. Methods A total of 70 cases with adolescent depression treated in the third people’s Hospital of Fuyang City, Anhui Province from May 2017 to September 2020 were selected as the object of study. According to the random number table method, they were divided into the control group and the observation group, with 35 cases in each group. The control group was treated with Sertraline combined with cognitive behavioral therapy; the observation group was treated with Escitalopram Oxalate combined with Cognitive behavioral therapy. After four weeks of continuous treatment, the severity of the disease and clinical efficacy were evaluated by hamilton depression scale (HAMD) and hamilton anxiety scale (HAMA), and the safety of drugs was evaluated by treatment emergent symptom scale (TESS). Results There was no significant difference in the total effective rate between the two groups after four weeks of treatment (P > 0.05); the scores of HAMD and HAMA were different in different time and group, and there was interaction between time and group, and the difference was statistically significant (all P < 0.05); further pairwise comparison showed that there were significant differences in HAMD and HAMA scores before treatment, the second week and the fourth week of treatment (P < 0.05); there was no significant difference in the scores of HAMD and HAMA between the two groups before treatment, the second week of treatment and the fourth week of treatment (P < 0.05); there was no significant difference in the incidence of ADR between the two groups (P > 0.05). Conclusion Escitalopram Oxalate and Sertraline combined with cognitive behavior therapy in adolescent patients with depression had satisfactory clinical effects and good tolerance, but sertraline had more adverse reactions.
邹亮1 张新功2 孙丽丽3 张玲玲4▲ 王瀚宇2. 草酸艾司西酞普兰与舍曲林分别联合认知行为治疗青少年抑郁症的临床对照研究[J]. 中国医药导报, 2021, 18(13): 141-144.
ZOU Liang1 ZHANG Xingong2 SUN Lili3 ZHANG Lingling4▲ WANG Hanyu2. Clinical control study of Escitalopram Oxalate and Sertraline combined with cognitive behavior in the treatment of adolescent depression. 中国医药导报, 2021, 18(13): 141-144.